Author Archive: BIOtechNOW Editor

Americans, Biotech Execs, Convention Attendees Optimistic About Biotech

Key Findings From A  National Survey Of Voters

What does the future hold for biotechnology? After surveying American voters, biotech executives, and attendees here the 2012 BIO International Convention, we learned that the future is indeed bright.  More than three quarters of American voters, nearly all the biotech execs, and 1,400 of the attendees we spoke to are optimistic that science and technology will find cures to help patients suffering from serious diseases, such as cancer, diabetes, Alzheimer’s, Parkinson’s and HIV/AIDS. Tempering that Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

An Insider’s View of the BioGENEius Challenge

BioGENEius Challenge

By Erica Hiar, Environics A big highlight every year for many attendees at BIO International Convention is the announcement of the winner of the International BioGENEius Challenge, a competition for high school students who demonstrate an exemplary understanding of biotechnology through science research projects. But for me, the true excitement was the ride getting there. Four hundred thirty-five students applied for the U.S. International BioGENEius challenge and hundreds more applied to the Canadian and Western Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

What’s the Buzz?

BuzzofBIOLogo

Meet Deuteria Pharmaceuticals, winner of the 2012 Buzz of BIO competition. What is Buzz of BIO? Companies from around the world enter for the chance to win free registration and a company presentation in the BIO Business Forum. Who won? Deuteria Pharmaceuticals, Inc., a company that is pioneering ‘Deuterium-Enabled Chiral Switching’ (DECS) to improve the profile of drugs that interconvert between enantiomers both in vitro and in vivo. Stabilizing the preferred isomer improves the product Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

Ernst & Young

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the state of the biotech industry, Beyond Borders, was buoyed by positive trends outlined in the report that show despite the overall lingering uneasiness in the economy, biotech is continuing its growth momentum. The Super Session at the 2012 BIO International Convention was moderated by members of Ernst & Young’s life sciences leadership team: Glen Giovannetti, Gautam Jaggi and Sanjeev Wadhwa; Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Prior User Rights and Trade Secrets

AA049539

By Joe Allen, President, Allen and Associates One theme of the day is the cloud of uncertainity overhanging the US patent system. This was underscored in the Prior User Rights and Trade Secrets session at the 2012 BIO International Convention as well. The new prior user rights defense which came into effect with enactment of the America Invents Act (AIA) was very differently viewed by the small biotech company perspective given by Mary Ann Dillahunty (Oncolytics Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,